title: Diagnosis of cancer-associated vascular disorders.
abstract: BACKGROUND
  Unexplained thromboembolism may be an early indicator of the presence of a malignant tumor before signs and symptoms of the tumor itself become obvious.
  
  
  METHODS
  A survey of the MEDLINE data-base was conducted concerning cancer-associated vascular disorders and their role in the diagnosis of hidden cancer. The spectrum of vascular disorders heralding occult cancer and the associated laboratory abnormalities were scrutinized.
  
  
  RESULTS
  Deep venous thrombosis was associated with a significantly higher frequency of malignancy during the first 6 months after diagnosis. Malignancies were found using simple clinical and diagnostic methods; additional screening was not cost-efficient. Other signs associated with deep venous thrombosis that increased the probability of an occult cancer were age older than 50 years, multiple sites of venous thrombosis, associated venous and arterial thromboembolism, thromboembolism resistant to warfarin therapy, and paraneoplastic syndrome. Among vascular syndromes, only cutaneous leukocytoclastic vasculitis presenting after the age of 50 years was consistently associated with cancer. Preliminary data with an antigen specific to tumor tissue, the cancer procoagulant, suggested its possible role as a tumor marker. The sensitivity for all samples analyzed from cancer patients was 80% and the specificity was 83%.
  
  
  CONCLUSIONS
  Data from the literature enabled us to outline clinical clues that might distinguish patients with cancer-associated vasculopathies from those unaffected by malignancies. Preliminary data with an antigen specific to tumor tissue, the cancer procoagulant, suggested its possible role in detecting early stage cancer. However, large-scale prospective studies are not currently available to evaluate the role of these clues and laboratory assays in the diagnosis of early stage cancer.
authors.affiliation: Department of Internal Medicine A, the Bnai Zion Medical Center, Haifa, Israel.
authors.forename: J E
authors.initials: JE
authors.lastname: Naschitz
authors.forename: D
authors.initials: D
authors.lastname: Yeshurun
authors.forename: S
authors.initials: S
authors.lastname: Eldar
authors.forename: L M
authors.initials: LM
authors.lastname: Lev
mesh_terms: D000367:Age Factors; D014408:Biomarkers, Tumor / Q000032:analysis; D001779:Blood Coagulation Factors / Q000032:analysis; D003546:Cysteine Endopeptidases / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis; D009382:Neoplasms, Unknown Primary / Q000150:complications / Q000175:diagnosis; D010257:Paraneoplastic Syndromes / Q000209:etiology*; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013923:Thromboembolism / Q000209:etiology; D013924:Thrombophlebitis / Q000209:etiology; D014652:Vascular Diseases / Q000209:etiology*; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000209:etiology
chemical_list: D014408:Biomarkers, Tumor; D001779:Blood Coagulation Factors; D009363:Neoplasm Proteins; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant